Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Mayo Clinic
Thomas Jefferson University
University of Utah
University of Utah
University of Utah
University of Washington
Sunnybrook Health Sciences Centre
University of Washington
Abramson Cancer Center at Penn Medicine
Jonsson Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Stanford University
Stanford University
Washington University School of Medicine
Children's Hospital of Philadelphia
Stanford University
Case Comprehensive Cancer Center
Maastricht Radiation Oncology